Maintenance of growth in cystic fibrosis despite reduction in pancreatic enzyme supplementation.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 9623407.
- Also identified by PMC identifier 1717525.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Twenty one children with cystic fibrosis were advised to decrease their pancreatic enzyme supplement (PES) dose to less than 10,000 units lipase/kg/day. Mean PES dosage was significantly decreased in 15 patients from 18,380 to 8647 units lipase/kg/day. There were no significant changes in energy or fat intake, but there were significant increases in weight SD score, height SD score, and weight/height ratio.
Medical subject headings
- Cystic Fibrosis
- Growth
- Lipase